Original Article
Routes of Infection, Viremia, and Liver Disease in Blood Donors Found to Have Hepatitis C Virus Infection
N Engl J Med 1996; 334:1691-1696June 27, 1996DOI: 10.1056/NEJM199606273342602
- Abstract
Background
For many people infected with the hepatitis C virus (HCV), the route of exposure, risk of transmission, and severity of associated liver disease are unknown. We studied these variables in people who donated blood voluntarily.
Methods
Blood donors who tested positive for HCV antibodies on enzyme immunoassay were classified according to whether the results of a confirmatory second-generation recombinant immunoblot assay (RIBA) for HCV were positive, negative, or indeterminate. The evaluations also included an assessment of risk factors, a physical examination, serial determinations of alanine aminotransferase levels and HCV serologic assays, a polymerase-chain-reaction assay for HCV RNA, testing of sexual contacts and family members, and liver biopsies in some participants who were HCV-positive by RIBA.
Results
A total of 481 donors were studied, among whom 248 were positive for HCV by RIBA, 102 had indeterminate results, and 131 were HCV-negative. In a logistic-regression analysis, significant risk factors for HCV infection among the HCV-positive participants were a history of blood transfusion in 66 (27 percent; P<0.001 for the comparison with RIBA-negative donors), intranasal cocaine use in 169 (68 percent, P<0.001), intravenous drug use in 103 (42 percent, P = 0.001), sexual promiscuity in 132 (53 percent, P = 0.002), and ear piercing among men (P<0.05). Nine of 85 sexual partners of HCV-positive donors were anti-HCV–positive; 8 had used intravenous drugs or received transfusions. HCV RNA was found in 213 HCV-positive donors (86 percent), 3 who had indeterminate results by RIBA (2 of these 3 tested positive with a more specific, third-generation RIBA), and none who were HCV-negative. Of the HCV-positive donors, 69 percent had biochemical evidence of chronic liver disease; among 77 donors positive for HCV by RIBA who underwent liver biopsy, 5 had severe chronic hepatitis or cirrhosis, 66 had mild-to-moderate chronic hepatitis, and 6 had no evidence of hepatitis.
Conclusions
Among volunteer blood donors, prior blood transfusion, intranasal cocaine use, intravenous drug use, sexual promiscuity, and ear piercing in men are risk factors for HCV infection. The high frequency of intravenous drug use was unexpected, because these donors had denied such use when questioned directly at the time of their blood donations.
Media in This Article
Figure 1
Frequency of Parenteral Exposure to HCV, Elevated Levels of Alanine Aminotransferase (ALT), and Detectable Serum Levels of HCV RNA in the Study Participants, According to the Results of a Second-Generation RIBA.Table 1
HCV Status as Determined by RIBA in the Study Participants and in All Blood Donations Found to Be Positive for Anti-HCV by Enzyme Immunoassay among 954,316 Consecutive Donations.Article Activity
- Article
Approximately 36,000 of the 6 million people who donate blood each year in the United States repeatedly test positive when screened for antibody to the hepatitis C virus (HCV),1 and about half are found to be carriers of HCV who require counseling and medical evaluation.2 The total number of such carriers in the United States may be as high as 3.5 million.3,4
To address controversial questions about the interpretation of HCV tests, patterns of transmission, and the severity of associated disease,5-12 we assessed the reliability and value of the supplemental recombinant immunoblot assay (RIBA) in diagnosing HCV infection; primary routes of HCV transmission in an asymptomatic population of blood donors; the infectivity of the persons confirmed to be anti-HCV–positive by the detection of HCV RNA in their blood and the study of their sexual partners, family members, or both; and the relation between positivity for anti-HCV and evidence of chronic liver disease.
Methods
Serologic Studies
Initially, anti-HCV was detected in the samples of donated blood by a first-generation enzyme immunoassay (EIA 1.0, Ortho Diagnostics, Raritan, N.J.) measuring reactivity to a nonstructural HCV antigen (C100-3). In June 1992, a second-generation assay (EIA 2.0, Ortho) was substituted that had greater sensitivity because it also detected reactivity to the HCV core protein (c22) and another nonstructural antigen (c33c). All the blood samples were assayed at the National Institutes of Health (NIH) by a second-generation RIBA (RIBA 2.0, Chiron, Emeryville, Calif.). In this assay, the antigens used in the second-generation enzyme immunoassay and a component of the C100-3 protein (5-1-1) were fixed to a nitrocellulose strip, overlaid with sample, allowed to react with enzyme-labeled antibody, and observed for a color change in the added solution of substrate. Reactivity to at least two of the four HCV antigens (5-1-1, C100-3, c33c, and c22) was considered to indicate a positive result; no reactivity, a negative result; and reactivity to only one antigen, an indeterminate result.
Enrollment of Patients, Initial Evaluation, and Follow-up
Volunteer donors of whole blood from the Greater Chesapeake and Potomac Region of the American Red Cross were screened for anti-HCV by enzyme immunoassay and RIBA; those whose donations repeatedly tested positive were notified by letter of the results of the initial assays and invited to enroll in the study beginning in March 1991. Because of limited resources, we could enroll only 10 percent of all potentially eligible donors. We sought to enroll 200 participants in the group positive for HCV by RIBA and 100 participants each in the group negative for HCV by RIBA and the group with indeterminate results by RIBA. Participants were enrolled consecutively until the approximate target numbers were reached. Donors who chose to be in the study but could not be enrolled were advised to seek follow-up care through their personal physicians; these donors and those who chose not to enroll were not contacted personally for additional information. However, a subgroup of these donors was randomly selected according to the results on the RIBA, and their demographic characteristics and transfusion histories were reviewed.
After the study participants provided written informed consent to the American Red Cross, information about them was released to the Department of Transfusion Medicine at the NIH, where the study was conducted. The study protocol was reviewed and approved by the institutional review boards of the NIH and the American Red Cross. Although the NIH physicians were generally aware of each donor's HCV status as determined by RIBA at the time of interview, the subjects were all evaluated in a standardized fashion regardless of their RIBA status. Medical histories were taken by a physician, including an extensive questionnaire about demographic variables, any history of hepatitis, risk factors for HCV exposure, and a sexual history. A second questionnaire about recreational drug use was completed in private by each participant. The physical examination focused on signs of chronic liver disease.
During the first year of the study, blood samples were obtained every three months to measure liver function and for the performance of HCV serologic tests. Participants negative for HCV by RIBA were considered to be uninfected and followed for 6 to 12 months, whereas those with positive or indeterminate results were enrolled in a long-term follow-up study that is anticipated to extend for at least 5 years.
All the participants were offered an assessment of their infectivity that included the testing of their sexual partners, children, and parents for anti-HCV. Contacts and family members who consented to such testing were asked about possible parenteral exposure to HCV.
Detection of HCV RNA by the Polymerase Chain Reaction
Serum samples from each participant were studied by the reverse-transcription polymerase-chain-reaction (PCR) assay at least once during follow-up for the detection of HCV RNA.13 Nucleotide primers corresponding to sequences in the 5' noncoding region of the HCV genome were used for amplification in the nested reverse-transcription PCR. The amplified gene product was identified by staining with ethidium bromide after gel electrophoresis. All specimens were tested in duplicate. If the test results were discrepant, another duplicate PCR was performed, and a specimen was considered to be HCV-positive if at least two of the four tests were positive.
Histologic Evaluation of Liver-Biopsy Specimens
Liver-biopsy specimens were obtained from 77 of the 248 participants who were positive for HCV by the second-generation RIBA; of these, 60 underwent biopsy as part of an adjunctive study relating the histologic activity of liver disease to serum alanine aminotransferase levels.3 All the biopsy specimens were analyzed by the NIH Anatomic Pathology Department and the Liver Section of the NIH and the National Institute of Diabetes and Digestive and Kidney Diseases. No biopsy specimens were obtained from participants with negative or indeterminate results on the RIBA.
Statistical Analysis
All the statistical analyses were performed with standard statistical software (SAS, Cary, N.C.; and BMDP, Los Angeles). The associations between HCV status and categorical variables (including the continuous variables, which were analyzed with cutoff values) were assessed with the unadjusted chi-square statistic, except that when the expected number in any cell of a two-by-two table was less than five, a two-tailed Fisher's exact test was used.14 The associations with continuous variables were assessed by the two-tailed Wilcoxon rank-sum statistic.15 A logistic-regression model16 was used in the multivariate modeling of associations. All the factors for which the P value on univariate analysis was less than 0.05 were entered in the model, but the factors with the highest P values on multivariate analysis were dropped sequentially until all the factors in the model had P values of less than 0.05.
Results
Anti-HCV Status
From March 1991 through August 1994, 954,316 consecutive blood donations were screened for anti-HCV by enzyme immunoassay; of these, 4585 (0.5 percent) repeatedly tested positive (Table 1Table 1
HCV Status as Determined by RIBA in the Study Participants and in All Blood Donations Found to Be Positive for Anti-HCV by Enzyme Immunoassay among 954,316 Consecutive Donations.), and 481 of those donors (10 percent) were enrolled in the study. All the donors with positive or indeterminate results on the RIBA were invited to enroll in the study, but only 1003 of the 1422 with negative results were invited to do so, because the target number of participants was rapidly reached. Of the 131 participants who were positive on the first-generation enzyme immunoassay and negative on the RIBA, 109 (83 percent) were anti-HCV–negative on the second-generation enzyme immunoassay.The final proportions of participants in the three study groups reflected the distribution of anti-HCV–positive donors in the overall donor population (Table 1). Of the 481 participants enrolled in the study, 382 had been followed for six months or more as of August 1994.
Demographic Variables
Comparison of Participants According to RIBA Status
The characteristics of the participants that were significantly associated with a positive RIBA for HCV were young age, black race, history of liver disease, no college education, no previous blood donation, and a history of sexually transmitted disease (Table 2Table 2
Characteristics of Blood Donors According to HCV Status.). The participants with indeterminate results on the RIBA were generally similar to those with negative results, but slightly larger proportions of the former were female, had no college education, and were giving blood for the first time.Comparison of the Study Participants with All Donors
Available demographic data on 1,267,295 donations of blood to the American Red Cross from January 1991 through December 1994 (a period that brackets the period of the study) were compared with the data on the study participants. The two groups were similar in terms of age, sex, and the percentage of African Americans. African Americans made up 10 percent of the overall donor population and 13 percent of the enrolled population (P = 0.08). Among the study participants there was a higher percentage of persons with no college education (38 percent vs. 28 percent of all donors, P<0.001), a lower percentage of first-time donors (15 percent vs. 19 percent, P = 0.01), and a higher percentage with a history of blood transfusions (18 percent vs. 9 percent, P = 0.02). The participants negative for HCV by RIBA were similar to the entire group of donors with respect to age, sex, race, and transfusion history (data not shown), but a higher percentage of the former had attended college or graduated from college (28 percent vs. 16 percent, P = 0.003), and a lower percentage were first-time donors (2 percent vs. 19 percent, P<0.001).
Comparison of the Study Participants with Nonparticipants
A sample of 181 donors distributed among the categories of HCV status as determined by RIBA was randomly selected from among those who chose not to enroll. The variables of sex, age, level of education, race, and transfusion history were similar between these donors and the study participants (data not shown). The percentage of first-time donors was higher among the donors who declined to enroll (22 percent, vs. 15 percent for the study participants; P = 0.03).
Risk Factors
The risk factors for exposure to HCV that were significantly associated with positivity for HCV on the RIBA in the logistic-regression analysis are shown in Table 3Table 3
Potential Risk Factors for Exposure to HCV in the Study Participants.. These factors were a history of blood transfusion in 66 participants (27 percent), intranasal cocaine use in 169 (68 percent), intravenous drug use in 103 (42 percent), and sexual promiscuity (defined as a history of sexually transmitted disease, sex with a prostitute, more than five sexual partners per year, or a combination of these) in 132 (53 percent). The high frequency of intravenous drug use was unexpected, since these participants had denied such use when they were questioned directly about it at the time of their blood donations. In the process of screening donors, intravenous drug use at any time in one's life was a reason for exclusion. Questions about blood transfusion, the exchange of sex for money or drugs, and sexually transmitted disease are limited to the year before the donation. Asking about cocaine use is not required in screening donors. Sixty-five percent of the transfusion recipients and 74 percent of the intravenous drug users reported that those events had taken place before 1980. A history of ear piercing was significantly associated with positive or indeterminate results on the RIBA among men, but there was no such association among women. Except for increased rates of intranasal cocaine use and ear piercing in the men with indeterminate results, the participants with indeterminate results were similar to those with negative results in having a low frequency of potential risk factors for exposure to HCV.A history of being tattooed or being imprisoned was associated with positive results by RIBA in the univariate analysis but not the multivariate analysis, because of the close association of these variables with intravenous drug use. Positive results by RIBA were not associated with employment in a health care profession, needle-stick injuries, or acupuncture treatments.
Follow-up questionnaires about intranasal cocaine use, completed by 137 of 169 participants positive for HCV by RIBA who acknowledged such use (81 percent), revealed that 115 (84 percent) shared straws during the cocaine use, 60 (44 percent) used cocaine intranasally three or more times per day, 40 (29 percent) had epistaxis during the cocaine use, and 37 (27 percent) observed epistaxis in others.
Transmission of HCV to Sexual Partners and Family Members
Sexual contacts and family members were tested for anti-HCV by the second-generation enzyme immunoassay (Table 4Table 4
Results of a Second-Generation Enzyme Immunoassay for Anti-HCV Performed among the Sexual Contacts and Family Members of 121 Anti-HCV–Positive Study Participants, According to the HCV Status of the Participants as Determined by RIBA.). The only contacts who tested positive for anti-HCV were the sexual partners of participants positive for HCV by RIBA. Of 85 such partners, 9 (11 percent) were positive for anti-HCV; 8 of these had used intravenous drugs or received transfusions. Similarly, two parents who tested positive for anti-HCV had histories of intravenous drug use or transfusion. Four of five children who tested positive were tested perinatally or as young children (under the age of 18 months). The positive results in these children may reflect the passive transfer of antibody, since none of them tested positive for HCV RNA by PCR. Follow-up testing for anti-HCV was negative in two of the children; the other two did not return for follow-up testing. The offspring with chronic HCV infection was a 36-year-old woman who had received multiple transfusions as a child in the 1970s. Overall, of a total of 141 contacts of participants with HCV, only 1, a sexual partner, had results of anti-HCV testing that could not be explained by prior parenteral exposure or the passive transfer of antibody.Detection of HCV RNA
HCV RNA was demonstrated in 213 participants with positive results by RIBA (86 percent), 3 participants with indeterminate results (3 percent), and no participants with negative results. Of 35 participants positive for HCV by RIBA but negative for HCV RNA, 34 were tested for HCV RNA at least twice (mean number of tests, 3; range, 2 to 7). PCR testing was always performed on the sample obtained at entry into the study, and subsequent tests were performed on samples obtained at intervals of three months or more. Hence, there was no evidence of intermittent viremia in the samples tested. Of the three participants with indeterminate results by RIBA who had viremia detectable by PCR, two tested positive with a more specific third-generation RIBA (RIBA 3.0, Chiron) that has not yet been licensed by the Food and Drug Administration.
Extent of Liver Disease
At the initial evaluation, biochemical evidence of liver disease was found in 138 of 248 participants positive for HCV by RIBA (56 percent) and in 11 of 131 participants negative for HCV (8 percent, P<0.001). When the follow-up period was included in the analysis, the percentage of participants with at least one elevated alanine aminotransferase measurement (upper limit of normal, 41 units per liter) increased to 69 percent among participants positive for HCV by RIBA and 15 percent among those negative for HCV (P<0.001). The median alanine aminotransferase level in the HCV-positive group was 48 units per liter (range, 4 to 556). During follow-up, most HCV-positive participants had either persistently normal alanine aminotransferase levels (31 percent) or peak levels no more than twice the upper limit of normal (42 percent). In 15 percent of HCV-positive participants, the alanine aminotransferase levels were more than twice the upper limit of normal, and in 12 percent they were more than three times that upper limit.
An elevated alanine aminotransferase level was strongly correlated with the presence of HCV RNA. Of 190 participants positive for HCV by RIBA who were followed for more than six months and had at least three blood samples tested, 110 of the 161 participants who had detectable HCV RNA (68 percent) had abnormal alanine aminotransferase levels, as compared with 5 of the 29 participants without detectable HCV RNA (17 percent, P<0.001). Conversely, 24 of 29 participants who tested negative for HCV RNA (13 percent of the 190 HCV-positive donors) had persistently normal alanine aminotransferase levels.
Of the 77 participants positive for HCV by RIBA who underwent liver biopsy, 6 (8 percent) had no histologic evidence of hepatitis; these 6 had normal alanine aminotransferase levels, and 5 of the 6 were negative for HCV RNA. Sixty-six (86 percent) had mild-to-moderate chronic hepatitis, and five (6 percent) had severe tissue lesions (indicating severe chronic hepatitis or cirrhosis). All the participants with severe lesions had detectable HCV RNA and peak alanine aminotransferase values more than twice the upper limit of normal.
No participant with HCV infection (who was positive for HCV by RIBA, positive for HCV RNA, or both) had characteristic symptoms of hepatitis. Fatigue was common, but its frequency was similar in infected and uninfected participants. HCV-related syndromes were detected in three participants with chronic infection, two with porphyria cutanea tarda, and one with essential mixed cryoglobulinemia.
Discussion
Although the available resources permitted the enrollment of only 10 percent of the more than 4000 donors identified as positive for anti-HCV, the demographic characteristics of the study participants and their HCV status as determined by RIBA suggested that the participants were generally similar to both the entire population of blood donors and those who did not enroll. Only the level of education and the proportion who were first-time donors differed. We used donors positive for HCV on enzyme immunoassay and negative by RIBA as a control group, rather than donors negative on enzyme immunoassay. This decision was based on cumulative data indicating that donors negative for HCV by RIBA are not infected with HCV.17 In our study, no participant positive by enzyme immunoassay and negative by RIBA was positive for HCV RNA or subsequently positive by RIBA. Furthermore, 83 percent of these participants later tested negative with the more specific second-generation enzyme immunoassay. Although on repeated testing 15 percent of participants negative by RIBA had slight elevations of alanine aminotransferase, these elevations did not appear to be related to HCV infection, as was evidenced by the absence of HCV RNA and markers of active infection with the hepatitis A and B viruses.
This study validates the efficacy of the RIBA in confirming the presence or absence of HCV infection in asymptomatic people. Most study participants who were positive for HCV by RIBA had risk factors for the parenteral acquisition of HCV, biochemical indexes of chronic hepatitis, and detectable HCV RNA, whereas there were very low rates of each of these factors in the participants negative by RIBA (Figure 1Figure 1
Frequency of Parenteral Exposure to HCV, Elevated Levels of Alanine Aminotransferase (ALT), and Detectable Serum Levels of HCV RNA in the Study Participants, According to the Results of a Second-Generation RIBA.). Aside from a slightly higher frequency of risk factors for parenteral HCV infection, the group with indeterminate results by RIBA was similar to the group with negative results (Table 3 and Figure 1). Indeterminate results are common with this assay, but only rarely do they indicate HCV infection.Positivity for HCV by RIBA was associated with younger age, lower educational level, and black race, factors also associated with hepatitis B virus and human immunodeficiency virus infections.18 These factors correlate with socioeconomic status and with routes of transmission, such as intravenous drug use, that are more common among the economically disadvantaged.
In the logistic-regression analysis, five factors were associated with confirmed HCV infection: intravenous drug use, blood transfusion, ear piercing in men, intranasal cocaine use, and sexual promiscuity. It is a matter of concern that a substantial number of participants — 23 percent of the cohort and 42 percent of participants positive for HCV by RIBA — acknowledged prior intravenous drug use in our study, even though they had denied such use at the time of screening. Only one study participant was currently using intravenous drugs; none considered themselves addicts or thought that their past intravenous drug use would affect the safety of their blood.19
If ear piercing in men is combined with other established sources of blood-borne HCV transmission,20-23 including transfusion, intravenous drug use, tattooing, acupuncture, and occupational exposure, then 75 percent of participants positive for HCV by RIBA had risk factors for parenteral transmission. Even this high proportion may be an underestimate, because some participants may not have been aware of a transfusion in the remote past or may not have revealed a history of intravenous drug use. HCV transmission by other routes may be a less important factor than previously suggested.5,24
The strong independent association between intranasal cocaine use and HCV infection raises the questions of whether that practice is a surrogate for other behavior that would foster transmission of the virus and whether the mechanics of intranasal cocaine use permit blood-borne transmission among users. If contaminated with blood, a device shared during intranasal cocaine use could convey virus to denuded nasal mucosa, allowing it to enter the bloodstream. Although this hypothesis was not proved in the present study, intranasal cocaine use could be an unrecognized route of parenteral transmission of HCV or other viruses.
The sexual transmission of HCV has been controversial.5,25-29 Our study showed a significant association between HCV infection and a history of sexual promiscuity. However, when we tested the long-term sexual partners of 85 participants positive for HCV by RIBA, only 1 partner was positive for anti-HCV and (according to that partner) had no other potential parenteral exposures. Although the possibility of sexual transmission of HCV has not been ruled out, these data imply, as do other studies,30,31 that such transmission is very inefficient.
The high frequency of detectable viremia in the study participants (86 percent) indicates that most people positive for HCV by RIBA are infected and infectious,32,33 but 13 percent of our participants who were positive on RIBA were HCV-negative by PCR on at least two occasions. This suggests that some people recover from HCV infection and retain specific antibody in the absence of viremia.
Finally, although biochemical and histologic evidence of chronic liver disease was common, elevations of serum alanine aminotransferase were slight and tissue lesions generally mild. Only 6 percent of participants positive for HCV by RIBA had severe histologic lesions, even though most had been infected for more than a decade.
Source Information
From the Department of Transfusion Medicine (C.C.-C., J.M., L.C., J.W.S., H.J.A.), the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (M.V., R.K.), and the National Institute of Diabetes and Digestive and Kidney Diseases (A.O.S., J.H.), National Institutes of Health, Bethesda, Md.; the Greater Chesapeake and Potomac Region American Red Cross, Baltimore (J.G., P.N.); the Hospital General Vall d'Hebron, Barcelona, Spain (L.V.); and the Department of Internal Medicine, St. Louis University Health Science Center, St. Louis (A.D.).
Address reprint requests to Dr. Conry-Cantilena at Bldg. 10, Rm. 1C711, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD 20892.
- References
References
1
Alter MJ . The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 1993;2:155-166
Medline2
McCullough J . The nation's changing blood supply system. JAMA 1993;269:2239-2245
CrossRef | Web of Science | Medline3
Shakil AO ,Conry-Cantilena C ,Alter HJ , et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995;123:330-337
Web of Science | Medline4
Alter MJ ,Mast EE . The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-455
Web of Science | Medline5
Alter MJ ,Hadler SC ,Judson FN , et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264:2231-2235
CrossRef | Web of Science | Medline6
Alter HJ . Descartes before the horse: I clone, therefore I am: the hepatitis C virus in current perspective. Ann Intern Med 1991;115:644-649
Web of Science | Medline7
Alter MJ ,Coleman PJ ,Alexander WJ , et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201-1205
CrossRef | Web of Science | Medline8
Alter MJ . Inapparent transmission of hepatitis C: footprints in the sand. Hepatology 1991;14:389-391
CrossRef | Web of Science | Medline9
Everhart JE ,Di Bisceglie AM ,Murray LM , et al. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990;112:544-545
Web of Science | Medline10
Alter HJ. Chronic consequences of non-A, non-B hepatitis. In: Seeff LB, Lewis JH, eds. Current perspectives in hepatology. New York: Plenum Medical, 1989:83-97.
11
Tong MJ ,El-Farra NS ,Reikes AR ,Co RL . Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466
Free Full Text | Web of Science | Medline12
Seeff LB ,Buskell-Bales Z ,Wright EC , et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911
Free Full Text | Web of Science | Medline13
Shindo M ,Di Bisceglie AM ,Cheung L , et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-704
Web of Science | Medline14
Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981.
15
Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: Iowa State University Press, 1980.
16
Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: John Wiley, 1989.
17
Cuthbert JA . Hepatitis C: progress and problems. Clin Microbiol Rev 1994;7:505-532
Web of Science | Medline18
Leitman SF ,Klein HG ,Melpolder JJ , et al. Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. N Engl J Med 1989;321:917-924
Full Text | Web of Science | Medline19
Conry-Cantilena C ,Melpolder JC ,VanRaden M ,Alter HJ . Characteristics and motivation of anti-HCV positive blood donors admitting intravenous drug use. Transfusion 1995;35:58S-58S abstract.
CrossRef | Web of Science20
Mitsui T ,Iwano K ,Masuko K , et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992;16:1109-1114
CrossRef | Web of Science | Medline21
Kiyosawa K ,Sodeyama T ,Tanaka E , et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991;115:367-369
Web of Science | Medline22
Abildgaard N ,Peterslund NA . Hepatitis C virus transmitted by tattooing needle. Lancet 1991;338:460-460
CrossRef | Web of Science | Medline23
Kiyosawa K ,Tanaka E ,Sodeyama T , et al. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. Gastroenterology 1994;106:1596-1602
Web of Science | Medline24
Alter MJ ,Margolis HS ,Krawczynski K , et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905
Free Full Text | Web of Science | Medline25
Eyster ME ,Alter HJ ,Aledort LA ,Goedert JJ . Cotransmission of hepatitis C virus (HCV) and human immunodeficiency virus from men with hemophilia to their sexual partners. Blood 1990;76:398a-398a abstract.26
Melbye M ,Biggar RJ ,Wantzin P ,Krogsgaard K ,Ebbesen P ,Becker NG . Sexual transmission of hepatitis C virus: cohort study (1981-9) among European homosexual men. BMJ 1990;301:210-212
CrossRef | Web of Science | Medline27
Lissen E ,Alter HJ ,Abad MA , et al. Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. Eur J Clin Microbiol Infect Dis 1993;12:827-831
CrossRef | Web of Science | Medline28
Eyster ME ,Alter HJ ,Aledort LM ,Quan S ,Hatzakis A ,Goedert JJ . Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991;115:764-768
Web of Science | Medline29
Esteban JI ,Esteban R ,Viladomiu L , et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989;2:294-297
CrossRef | Web of Science | Medline30
Brettler DB ,Mannucci PM ,Gringeri A , et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. Blood 1992;80:540-543
Web of Science | Medline31
Weinstock HS ,Bolan G ,Reingold AL ,Polish LB . Hepatitis C virus infection among patients attending a clinic for sexually transmitted diseases. JAMA 1993;269:392-394
CrossRef | Web of Science | Medline32
Aach RD ,Stevens CE ,Hollinger FB , et al. Hepatitis C virus infection in post-transfusion hepatitis -- an analysis with first- and second-generation assays. N Engl J Med 1991;325:1325-1329
Free Full Text | Web of Science | Medline33
Alter HJ ,Purcell RH ,Shih JW , et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500
Full Text | Web of Science | Medline
- Citing Articles (269)
Citing Articles
1
Mark AA Claassen, Harry LA Janssen, André Boonstra. (2013) Role of T cell immunity in hepatitis C virus infections. Current Opinion in Virology
2
Kerrilynn Carney, Sameer Dhalla, Ayse Aytaman, Craig T. Tenner, Fritz Francois. (2013) Association of tattooing and hepatitis C virus infection: A multicenter case-control study. Hepatology 57:6, 2117-2123
3
Kei Fujiwara, Robert D. Allison, Richard Y. Wang, Patricia Bare, Kentaro Matsuura, Cathy Schechterly, Krishna Murthy, Francesco M. Marincola, Harvey J. Alter. (2013) Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology 57:2, 483-491
4
Erdem Akbal, Seyfettin Köklü, Erdem Koçak, Başak Çakal, Fahri Güneş, Ömer Başar, Yaşar Tuna, Mehmet Şenes. (2013) Liver Fatty Acid-binding Protein Is A Diagnostic Marker to Detect Liver Injury Due to Chronic Hepatitis C Infection. Archives of Medical Research 44:1, 34-38
5
Gideon P. Smith. Animal Models of Fibrosis in Human Disease. In: Animal Models for the Study of Human Disease. Elsevier, 2013:435-458.
6
A. Nafishah, M. Nor Asiah, A. T. Nur Syimah, T. H. Mohd Zahari, A. Yasmin, M. Normi, E. Anza, M. Shahnaz, M. Y. Narazah. (2012) Rate of Seroconversion in Repeat Blood Donors at The National Blood Centre, Kuala Lumpur. Indian Journal of Hematology and Blood Transfusion
7
Zhengtao Liu, Yanling Hu, Xiaobo Yang, Aihua Tan, Yong Gao, Xue Qin, Yu Liang, Zengnan Mo, Tao Peng. (2012) Combinative analysis of factors influence serum alanine aminotransferase activity in adult male population from southern China. Clinical Biochemistry 45:18, 1683-1688
8
Momoka Otsuka, Yuki Uchida, Takumi Kawaguchi, Eitaro Taniguchi, Atsushi Kawaguchi, Shingo Kitani, Minoru Itou, Tetsuharu Oriishi, Tatsuyuki Kakuma, Suiko Tanaka, Minoru Yagi, Michio Sata. (2012) Fish to meat intake ratio and cooking oils are associated with hepatitis C virus carriers with persistently normal alanine aminotransferase levels. Hepatology Research 42:10, 982-989
9
Mari-Lynn Drainoni, Alain N. Litwin, Bryce D. Smith, Elisa A. Koppelman, M. Diane McKee, Cindy L. Christiansen, Allen L. Gifford, Cindy M. Weinbaum, William N. Southern. (2012) Effectiveness of a Risk Screener in Identifying Hepatitis C Virus in a Primary Care Setting. American Journal of Public Healthe1-e7
10
R. D. Allison, C. Conry-Cantilena, D. Koziol, C. Schechterly, P. Ness, J. Gibble, D. E. Kleiner, M. G. Ghany, H. J. Alter. (2012) A 25-Year Study of the Clinical and Histologic Outcomes of Hepatitis C Virus Infection and Its Modes of Transmission in a Cohort of Initially Asymptomatic Blood Donors. Journal of Infectious Diseases 206:5, 654-661
11
Addisalem T. Makuria, Sukanya Raghuraman, Peter D. Burbelo, Cathy C. Cantilena, Robert D. Allison, Joan Gibble, Barbara Rehermann, Harvey J. Alter. (2012) The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling. Transfusion 52:9, 1940-1948
12
María J. Bravo, Fernando Vallejo, Gregorio Barrio, M. Teresa Brugal, Gemma Molist, José Pulido, Luis Sordo, Luis de la Fuente. (2012) HCV seroconversion among never-injecting heroin users at baseline: No predictors identified other than starting injection. International Journal of Drug Policy 23:5, 415-419
13
K. A. Hermanstyne, D. R. Bangsberg, K. Hennessey, C. Weinbaum, J. A. Hahn. (2012) The association between use of non-injection drug implements and hepatitis C virus antibody status in homeless and marginally housed persons in San Francisco. Journal of Public Health 34:3, 330-339
14
Michelle Spaan, Harry L.A. Janssen, Andre Boonstra. (2012) Immunology of hepatitis C virus infections. Best Practice & Research Clinical Gastroenterology 26:4, 391-400
15
Matthew F Cusick, Jane E Libbey, Robert S Fujinami, David D Eckels. (2012) In vitro antigen-specific induction of IL-22 in human subjects that resolved HCV infection. Future Virology 7:7, 719-728
16
Francisco José Dutra Souto, Cor Jésus Fernandes Fontes, Luara Teófilo Pignati, Maria Emiliana Sarno Pagliarini, Valfredo da Mota Menezes, Ana de Lourdes Candolo Martinelli, José Fernando de Castro Figueiredo, Eduardo Antonio Donadi, Afonso Diniz Passos. (2012) Risk factors for hepatitis C virus infection in Inland Brazil: An analysis of pooled epidemiological sectional studies. Journal of Medical Virology 84:5, 756-762
17
Junko Matsuo, Masaaki Mizui, Hajime Okita, Keiko Katayama, Shiomi Aimitsu, Tatsuro Sakata, Makoto Obayashi, Toshio Nakanishi, Kazuaki Chayama, Yuzo Miyakawa, Hiroshi Yoshizawa, Junko Tanaka, . (2012) Follow up of the 987 blood donors found with hepatitis C virus infection over 9-18 years. Hepatology Researchno-no
18
Andrea Domanico, Monica Malta. (2012) Implementation of Harm Reduction Toward Crack Users in Brazil: Barriers and Achievements. Substance Use & Misuse 47:5, 535-546
19
R. A. Tohme, S. D. Holmberg. (2012) Transmission of Hepatitis C Virus Infection Through Tattooing and Piercing: A Critical Review. Clinical Infectious Diseases
20
Gideon P. Smith. Animal Models of Cutaneous and Hepatic Fibrosis. Elsevier, 2012:371-409.
21
Alyson N. Fox, Lennox J. Jeffers, Rajender Reddy. Liver Biopsy and Laparoscopy. In: Schiff's Diseases of the Liver. Wiley-Blackwell, 2011:44-57.
22
Hussein H. Aly, Kunitada Shimotohno, Makoto Hijikata, Tsukasa Seya. (2011) In vitro models for the analysis of HCV life cycle. Microbiology and Immunologyno-no
23
K. A. Forde, K. Haynes, A. B. Troxel, S. Trooskin, M. T. Osterman, S. E. Kimmel, J. D. Lewis, V. Lo Re. (2011) Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study*. Journal of Viral Hepatitisno-no
24
Jae Y. Cheong, Dong J. Kim, Seong G. Hwang, Jin M. Yang, Young B. Kim, Young N. Park, Sung W. Cho. (2011) Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels. Liver International 31:9, 1352-1358
25
L. M. Kucirka, H. Sarathy, P. Govindan, J. H. Wolf, T. A. Ellison, L. J. Hart, R. A. Montgomery, R. L. Ros, D. L. Segev. (2011) Risk of Window Period Hepatitis-C Infection in High Infectious Risk Donors: Systematic Review and Meta-Analysis. American Journal of Transplantation 11:6, 1188-1200
26
Yi He, Jie Zhang, Li Zhong, Xue Chen, Hu-Min Liu, Li-Ke Wan, Huan Wang, Hong Li, Li Tian, Jin-Liang Hu, Ping Luo, Lei Wang, Yan Chen, Tao Liu, Shuang-Li Liu, Wen-Bin Lü. (2011) Prevalence of and risk factors for hepatitis C virus infection among blood donors in Chengdu, China. Journal of Medical Virology 83:4, 616-621
27
Melanie C.M. Murray, Rolando Barrios, Wendy Zhang, Mark Hull, Valentina Montessori, Robert S. Hogg, Julio S.G. Montaner. (2011) Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. European Journal of Gastroenterology & Hepatology 23:1, 45-50
28
Paul J Clark, Alex J Thompson, John G McHutchison. (2011) IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV Therapies. The American Journal of Gastroenterology 106:1, 38-45
29
Diana Nurutdinova, Arbi B Abdallah, Susan Bradford, Catina C O'Leary, Linda B Cottler. (2011) Risk factors associated with Hepatitis C among female substance users enrolled in community-based HIV prevention studies. BMC Research Notes 4:1, 126
30
Anne Grogan, Fiona Timmins. (2010) Patients’ perceptions of information and support received from the nurse specialist during HCV treatment. Journal of Clinical Nursing 19:19-20, 2869-2878
31
R. BEHAL, R. JAIN, K. K. BEHAL, T. N. DHOLE. (2010) Variation in the host ABO blood group may be associated with susceptibility to hepatitis C virus infection. Epidemiology and Infection 138:08, 1096-1099
32
Licui Wang, Qiuxia Fu, Yafeng Dong, Yong Zhou, Shuaizheng Jia, Juan Du, Fang Zhao, Yingli Wang, Xiaohui Wang, Jianchun Peng, Shuhua Yang, Linsheng Zhan. (2010) Bioluminescence imaging of Hepatitis C virus NS3/4A serine protease activity in cells and living animals. Antiviral Research 87:1, 50-56
33
K. Yusim, W. Fischer, H. Yoon, J. Thurmond, P. W. Fenimore, G. Lauer, B. Korber, C. Kuiken. (2010) Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. Journal of General Virology 91:5, 1194-1206
34
Nazish Bostan, Tariq Mahmood. (2010) An overview about hepatitis C: A devastating virus. Critical Reviews in Microbiology 36:2, 91-133
35
Hitoshi Ohto, Tsutomu Ishii, Junichi Kitazawa, Seiji Sugiyama, Niro Ujiie, Keiya Fujimori, Hiromichi Ariga, Tomoko Satoh, Kenneth E. Nollet, Hiroaki Okamoto, Tanji Hoshi. (2010) TRANSFUSION COMPLICATIONS: Declining hepatitis C virus (HCV) prevalence in pregnant women: impact of anti-HCV screening of donated blood. Transfusion 50:3, 693-700
36
Michiyasu Yagura, Akihisa Tanaka, Hiroshi Kamitsukasa, Hiroki Otsuka, Sotaro Kanno, Toshihisa Aoyama. (2010) Re-evaluation of the Serum Alanine Aminotransferase Upper Normal Limit in Chronic Hepatitis C Patients. Internal Medicine 49:6, 525-528
37
D.J. Hu, W.A. Bower, J.W. Ward. Viral Hepatitis. In: Atlas of Sexually Transmitted Diseases and AIDS. Elsevier, 2010:203-229.
38
KENT A. SEPKOWITZ, MATTHEW J. KUEHNERT. Nosocomial Hepatitis and Other Transfusion- and Transplantation-Transmitted Infections. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:3739-3751.
39
STUART C. RAY, DAVID L. THOMAS. Hepatitis C. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:2157-2185.
40
JULES L. DIENSTAG. Chronic Viral Hepatitis. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:1593-1617.
41
Andre Boonstra, Luc J. W. van der Laan, Thomas Vanwolleghem, Harry L. A. Janssen. (2009) Experimental models for hepatitis C viral infection. Hepatology 50:5, 1646-1655
42
L. A. King, Y. Le Strat, C. Meffre, E. Delarocque-Astagneau, J.-C. Desenclos. (2009) Assessment and proposal of a new combination of screening criteria for hepatitis C in France. The European Journal of Public Health 19:5, 527-533
43
A. Lawson, . (2009) Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease?. Journal of Viral Hepatitis
44
Teruo Miyazaki, Akira Honda, Tadashi Ikegami, Takashi Hara, Yoshifumi Saitoh, Takeshi Hirayama, Mikio Doy, Yasushi Matsuzaki. (2009) The associated markers and their limitations for the primary screening of HCV carriers in public health examination. Hepatology Research 39:7, 664-674
45
Mindy Goldman, Guoliang Xi, Qi-Long Yi, Wenli Fan, Sheila F. O'Brien. (2009) Reassessment of deferrals for tattooing and piercing. Transfusion 49:4, 648-654
46
Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff. (2009) Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:4, 1335-1374
47
Volker Meier, Giuliano Ramadori. (2009) Hepatitis C virus virology and new treatment targets. Expert Review of Anti-infective Therapy 7:3, 329-350
48
ELIZABETH I. HARRIS, KAY WASHINGTON, LAURA W. LAMPS. Acute and Chronic Infectious Hepatitis. In: Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Elsevier, 2009:1003-1033.
49
Prem H. Thurairajah, Doha Hegazy, Shilpa Chokshi, Steve Shaw, Andrew Demaine, Edward R. Kaminski, Nikolai V. Naoumov, Matthew E. Cramp. (2008) Hepatitis C Virus (HCV)–Specific T Cell Responses in Injection Drug Users with Apparent Resistance to HCV Infection. The Journal of Infectious Diseases 198:12, 1749-1755
50
Andre Boonstra, Andrea M. Woltman, Harry L.A. Janssen. (2008) Immunology of hepatitis B and hepatitis C virus infections. Best Practice & Research Clinical Gastroenterology 22:6, 1049-1061
51
Ana M. Contreras, Claudia M. Tornero-Romo, José G. Toribio, Alfredo Celis, Axel Orozco-Hernández, P. Kristian Rivera, Claudia Méndez, M. Isabel Hernández-Lugo, Laura Olivares, Martha A. Alvarado. (2008) Very low hepatitis C antibody levels predict false-positive results and avoid supplemental testing. Transfusion 48:12, 2540-2548
52
Sagiv Aaron, James M. McMahon, Danielle Milano, Leilani Torres, Michael Clatts, Stephanie Tortu, Donna Mildvan, Malgorzata Simm. (2008) Intranasal Transmission of Hepatitis C Virus: Virological and Clinical Evidence. Clinical Infectious Diseases 47:7, 931-934
53
Raveen Parboosing, Imran Paruk, Umesh G. Lalloo. (2008) Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naïve patients is associated with renal insufficiency and increased mortality. Journal of Medical Virology 80:9, 1530-1536
54
Hla-Hla Thein, Qilong Yi, Gregory J. Dore, Murray D. Krahn. (2008) Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology 48:2, 418-431
55
Fredric D. Gordon. (2008) DISPARATE LIVER TEST RESULTS? TIEBREAKER GOES TO THE CLINICIAN. Evidence-Based Gastroenterology 9:3, 51-52
56
Juan Macías, Rosa B. Palacios, Evangelina Claro, Julio Vargas, Salvador Vergara, José A. Mira, Nicolás Merchante, Juan E. Corzo, Juan A. Pineda. (2008) High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver International 28:6, 781-786
57
D. Hegazy, P. Thurairajah, M. Metzner, A. Houldsworth, S. Shaw, E. Kaminski, A. G. Demaine, M. E. Cramp. (2008) Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection. Clinical & Experimental Immunology 152:3, 538-541
58
Sheila F. O'Brien, Wenli Fan, Guoliang Xi, Qi-Long Yi, Mindy Goldman, Margaret A. Fearon, Claire Infante-Rivard, Jo Anne Chiavetta, Bernard Willems, David Pi, Margaret Fast, Gilles Delage. (2008) Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion 48:5, 902-909
59
Muhammad IDREES, Amreek LAL, Muhammad NASEEM, Muhammad KHALID. (2008) High prevalence of hepatitis C virus infection in the largest province of Pakistan. Journal of Digestive Diseases 9:2, 95-103
60
W. Ray Kim, Steven L. Flamm, Adrian M. Di Bisceglie, Henry C. Bodenheimer. (2008) Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47:4, 1363-1370
61
Yeon Seok Seo. (2008) Normal range of serum ALT level in patients with chronic hepatitis. The Korean Journal of Hepatology 14:1, 116
62
Myoung Joo Kang, Eun Uk Jung, Sang Won Park, Paul Choi, Ji Hyun Kim, Sung Jae Park, Eun Taek Park, Youn Jae Lee, Sang Hyuk Lee, Sang Yong Seol. (2008) Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection. The Korean Journal of Hepatology 14:3, 318
63
Hojun Lee, Yoo-Kyung Cho, Heung Up Kim, Eun Kwang Choi, Soyoung Hyun, Donggu Kang, Seung Uk Jeong, Hyun Ju Kim, Kwang Sik Kim, Byung-Cheol Song. (2008) Distribution of hepatitis C virus genotypes in Jeju Island. The Korean Journal of Hepatology 14:1, 28
64
Judith A. Luce. Use of Blood Components in the Intensive Care Unit. In: Critical Care Medicine. Elsevier, 2008:1655-1675.
65
Anne M. Hickey, Hannah M. McGee, Mary Smith, Frank Murray. (2008) Iatrogenesis and hepatitis C infection: Implications for well-being. The Irish Journal of Psychology 29:1-2, 19-33
66
Bernard Gonik. (2008) The Role of Obstetrician/Gynecologists in the Management of Hepatitis C Virus Infection. Infectious Diseases in Obstetrics and Gynecology 2008, 1-7
67
Karen H Seal, Alex Monto, Lorna Dove, Hui Shen, Eric Vittinghoff, Daniel Tracy, Erica Miller, Eva Lau, Teresa L. Wright. (2007) The Association of Human Immunodeficiency Virus Infection with Spontaneously Resolved Hepatitis C Virus Infection and Level of Viremia Among Injection Drug Users. Digestive Diseases and Sciences 52:12, 3423-3430
68
Mark S. Sulkowski. (2007) Hepatitis C virus infection in HIV-infected patients. Current Infectious Disease Reports 3:5, 469-476
69
Antonio Picardi, Umberto Vespasiani Gentilucci, Federica Bambacioni, Giovanni Galati, Sandro Spataro, Chiara Mazzarelli, Delia D’Avola, Enrica Fiori, Elisabetta Riva. (2007) Lower schooling, higher hepatitis C virus prevalence in Italy: An association dependent on age. Journal of Clinical Virology 40:2, 168-170
70
Lucas C. Quarantini, Rodrigo A. Bressan, Amanda Galvão, Susana Batista-Neves, Raymundo Paraná, Ângela Miranda-Scippa. (2007) Incidence of psychiatric side effects during pegylated interferon- ? retreatment in nonresponder hepatitis C virus-infected patients. Liver International 27:8, 1098-1102
71
O. Freudenreich, R. T. Gandhi, J. P. Walsh, D. C. Henderson, D. C. Goff. (2007) Hepatitis C in Schizophrenia: Screening Experience in a Community-Dwelling Clozapine Cohort. Psychosomatics 48:5, 405-411
72
Mark N. Polizzotto, Erica M. Wood, Helen Ingham, Anthony J. Keller, . (2007) Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006. Transfusion 0:0, 071003012013002-???
73
Ayako Hayashida, Noriyuki Inaba, Kyoko Oshima, Masayoshi Nishikawa, Akiko Shoda, Shihou Hayashida, Masami Negishi, Fujiyuki Inaba, Michiyo Inaba, Ichio Fukasawa, Hiroshi Watanabe, Hiroyoshi Takamizawa. (2007) Re-evaluation of the true rate of hepatitis C virus mother-to-child transmission and its novel risk factors based on our two prospective studies. Journal of Obstetrics and Gynaecology Research 33:4, 417-422
74
Hana Kerzman, Manfred S. Green, Eilat Shinar. (2007) Risk factors for hepatitis
C virus infection among blood donors in Israel: a case-control study between native Israelis and immigrants from the former Soviet Union. Transfusion 47:7, 1189-1196
75
Ivana Maida, Vincent Soriano, Pablo Barreiro, Pablo Rivas, Pablo Labarga, Marina Núñez. (2007) Liver Fibrosis Stage and HCV Genotype Distribution in HIV–HCV Coinfected Patients with Persistently Normal Transaminases. AIDS Research and Human Retroviruses 23:6, 801-804
76
Anne M. Wertheimer, Stephen J. Polyak, Rachel Leistikow, Hugo R. Rosen. (2007) Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells. Hepatology 45:6, 1422-1432
77
Roberta Scheinmann, Holly Hagan, Corina Lelutiu-Weinberger, Rebecca Stern, Don C. Des Jarlais, Peter L. Flom, Shiela Strauss. (2007) Non-injection drug use and Hepatitis C Virus: A systematic review. Drug and Alcohol Dependence 89:1, 1-12
78
M. SIMIN, J. BROK, D. STIMAC, C. GLUUD, L. L. GLUUD. (2007) Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Alimentary Pharmacology & Therapeutics 25:10, 1153-1162
79
Naomi L.C. Luban, Camilla A. Colvin, Parvathi Mohan, Harvey J. Alter. (2007) The epidemiology of transfusion-associated hepatitis
80
Markus Backmund. (2007) Ansprechbarkeit von Drogengebrauchern über Infektionsrisiken für HIV und HCV. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 50:4, 471-475
81
Jaydeep S. Kadam, Andrew H. Talal. (2007) Changing Treatment Paradigms: Hepatitis C Virus in HIV-Infected Patients. AIDS Patient Care and STDs 21:3, 154-168
82
Louis M. Katz, Paul D. Cumming, Edward L. Wallace. (2007) Computer-Based Blood Donor Screening: A Status Report. Transfusion Medicine Reviews 21:1, 13-25
83
Erwin Chiquete, Arturo Panduro. (2007) Low Prevalence of Anti-Hepatitis C Virus Antibodies in Mexico: A Systematic Review. Intervirology 50:1, 1-8
84
Roger Y. Dodd. Hepatitis C. In: Blood Banking and Transfusion Medicine. Elsevier, 2007:592-599.
85
C. W. Wester, H. Bussmann, S. Moyo, A. Avalos, T. Gaolathe, N. Ndwapi, M. Essex, R. R. MacGregor, R. G. Marlink. (2006) Serological Evidence of HIV-Associated Infection among HIV-1--Infected Adults in Botswana. Clinical Infectious Diseases 43:12, 1612-1615
86
Ming-Lung Yu, Chia-Yen Dai, Li-Po Lee, Nei-Jen Hou, Ming-Yen Hsieh, Jee-Fu Huang, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang. (2006) A 24-week course of high-dose interferon-? plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Liver International 26:10, 1187-1195
87
Chen-Hua Liu, Jou-Wei Lin, Feng-Chiao Tsai, Pei-Ming Yang, Ming-Yang Lai, Jun-Herng Chen, Jia-Horng Kao, Ding-Shinn Chen. (2006) Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver International 26:9, 1087-1094
88
M. Karmochkine, F. Carrat, O. Dos Santos, P. Cacoub, G. Raguin, . (2006) A case?control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. Journal of Viral Hepatitis 13:11, 775-782
89
S. ZEUZEM, A. ALBERTI, W. ROSENBERG, P. MARCELLIN, M. DIAGO, F. NEGRO, D. PRATI, C. PUOTI, S. K. ROBERTS, M. L. SHIFFMAN. (2006) Review article: management of patients with chronic hepatitis C virus infection and 'normal' alanine aminotransferase activity. Alimentary Pharmacology and Therapeutics 24:8, 1133-1149
90
Akke K. Van der Bij, Roel A. Coutinho, Cees L. Van der Poel. (2006) Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands. Transfusion 46:10, 1729-1736
91
Thijs J.W. van de Laar, Marco H.G.M. Koppelman, Akke K. van der Bij, Hans L. Zaaijer, H. Theo M. Cuijpers, Cees L. van der Poel, Roel A. Coutinho, Sylvia M. Bruisten. (2006) Diversity and origin of hepatitis
92
Rachel Gonzales, Patricia Marinelli-Casey, Steven Shoptaw, Alfonso Ang, Richard A. Rawson. (2006) Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. Journal of Substance Abuse Treatment 31:2, 195-202
93
Perdita Wietzke-Braun, Adil B. Maouzi, Larissa B. M??nhardt, Heike Bickeb??ller, Giuliano Ramadori, Sabine Mihm. (2006) Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection. European Journal of Gastroenterology & Hepatology 18:9, 991-997
94
Lu-Yu Hwang, Jennifer R. Kramer, Catherine Troisi, Lara Bull, Carolyn Z. Grimes, Rob Lyerla, Miriam J. Alter. (2006) Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. Hepatology 44:2, 341-351
95
Stevan A. Gonzalez, Ruei-Che Liu, Brian R. Edlin, Ira M. Jacobson, Andrew H. Talal. (2006) HIV/Hepatitis C Virus-Coinfected Patients With Normal Alanine Aminotransferase Levels. JAIDS Journal of Acquired Immune Deficiency Syndromes 41:5, 582-589
96
M. Rios, M. Diago, P. Rivera, C. Tuset, R. Cors, V. Garcia, P. Carbonel, C. Gonzalez. (2006) Epidemiological, biological and histological characterization of patients with indeterminate third-generation recombinant immunoblot assay antibody results for hepatitis C virus. Journal of Viral Hepatitis 13:3, 177-181
97
E. J. BINI, S. MEHANDRU. (2006) Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Alimentary Pharmacology and Therapeutics 23:6, 777-785
98
Masashi Mizokami, Yasuhito Tanaka, Yuzo Miyakawa. (2006) Spread Times of Hepatitis C Virus Estimated by the Molecular Clock Differ among Japan, the United States and Egypt in Reflection of Their Distinct Socioeconomic Backgrounds. Intervirology 49:1-2, 28-36
99
Takeji Umemura, Richard Y.-H. Wang, Cathy Schechterly, J. Wai-Kuo Shih, Kendo Kiyosawa, Harvey J. Alter. (2006) Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology 43:1, 91-99
100
Maher K. Gandhi, Rajiv Khanna. (2005) Viruses and lymphoma. Pathology 37:6, 420-433
101
David J. Gocke, Linda Silvay. (2005) Infectious Disease Risk of Cadaveric Tissue Donors Who Used Non-injected Illicit Drugs. Cell and Tissue Banking 6:4, 249-253
102
Holly Hagan, Hanne Thiede, Don C Des Jarlais. (2005) HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS 19:Suppl 3, S199-S207
103
Jason Hunt, Joseph Hagan, James Nobles, Christian Wold, Mary Fazekas-May, Jill Gilbert, Paul L. Friedlander. (2005) Outcome Analysis of Patients with Squamous Cell Carcinoma of the Head and Neck and Hepatitis C Virus. The Laryngoscope 115:10, 1882-1886
104
Chanelle J. Howe, Crystal M. Fuller, Danielle C. Ompad, Sandro Galea, Beryl Koblin, David Thomas, David Vlahov. (2005) Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug and Alcohol Dependence 79:3, 389-395
105
Lawrence Goodnough, George Despotis. Transfusion Therapy and the Cancer Patient. In: Acute Care of the Cancer Patient. CRC Press, 2005:519-536.
106
Andrew I. Kim, Sammy Saab. (2005) Treatment of hepatitis C. The American Journal of Medicine 118:8, 808-815
107
Marija Simin, Jesper Brok, Davor Stimac, Christian Gluud, Lise Lotte Gluud, Marija Simin. Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2005.
108
A. Libois, E. Fumero, P. Castro, M. Nomdedeu, A. Cruceta, J. M. Gatell, F. Garcia. (2005) Transmission of Hepatitis C Virus by Discarded-Needle Injury. Clinical Infectious Diseases 41:1, 129-130
109
Simone A. Glynn, David J. Wright, Steven H. Kleinman, Dale Hirschkorn, Yongling Tu, Charles Heldebrant, Richard Smith, Cristina Giachetti, James Gallarda, Michael P. Busch. (2005) Dynamics of viremia in early hepatitis C virus infection. Transfusion 45:6, 994-1002
110
Mark Evans, Patricia S Hokanson, Jay Augsburger, Shelly L Sayre, Angela L Stotts, Joy M Schmitz. (2005) Increasing Knowledge of HIV and Hepatitis C During Substance Abuse Treatment. Addictive Disorders & Their Treatment 4:2, 71-76
111
Michael Schmidt, Marijke Weber, Michael P. Busch, Leslie H. Tobler, Bruce H. Phelps, Erhard Seifried, W. Kurt Roth. (2005) Yield of hepatitis C virus nucleic acid testing among antibody-reactive or confirmed-positive samples. Transfusion 45:6, 1040-1042
112
Lawrence T. Goodnough. (2005) Risks of Blood Transfusion. Anesthesiology Clinics of North America 23:2, 241-252
113
Markus Backmund, Jens Reimer, Kirsten Meyer, J. Tilman Gerlach, Reinhart Zachoval. (2005) Hepatitis C Virus Infection and Injection Drug Users: Prevention, Risk Factors, and Treatment. Clinical Infectious Diseases 40:s5, S330-S335
114
Adeel A Butt. (2005) Hepatitis C virus infection: the new global epidemic. Expert Review of Anti-infective Therapy 3:2, 241-249
115
C. A. Benson, J. E. Kaplan, H. Masur, A. Pau, K. K. Holmes. (2005) Treating Opportunistic Infections among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clinical Infectious Diseases 40:Supplement 3, S131-S235
116
Alfredo Alberti. (2005) Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. Journal of Hepatology 42:2, 266-274
117
Markus Backmund, Kirsten Meyer, Claudia Henkel, Jens Reimer, Martin Wächtler, Christian G. Schütz. (2005) Risk Factors and Predictors of Human Immunodeficiency Virus Infection among Injection Drug Users. European Addiction Research 11:3, 138-144
118
(2005) Hepatitis C Virus (HCV). Transfusion Medicine and Hemotherapy 32:3-4, 184-195
119
Jason A. Dominitz, Edward J. Boyko, Thomas D. Koepsell, Patrick J. Heagerty, Charles Maynard, Jennifer L. Sporleder, . (2005) Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 41:1, 88-96
120
R. Moreno-Otero. (2005) Therapeutic modalities in hepatitis C: challenges and development. Journal of Viral Hepatitis 12:1, 10-19
121
A. DiMartini. (2004) Pretransplant Psychiatric and Medical Comorbidity of Alcoholic Liver Disease Patients Who Received Liver Transplant. Psychosomatics 45:6, 517-523
122
Lakkana Thaikruea, Satawat Thongsawat, Niwat Maneekarn, Dale Netski, David L. Thomas, Kenrad E. Nelson. (2004) Risk factors for hepatitis C virus infection among blood donors in northern Thailand. Transfusion 44:10, 1433-1440
123
A. Alberti, L. Benvegnù, S. Boccato, A. Ferrari, G. Sebastiani. (2004) Natural history of initially mild chronic hepatitis C. Digestive and Liver Disease 36:10, 646-654
124
Lorna M. Dove. (2004) A general approach to the management of chronic hepatitis C. Gastroenterology Clinics of North America 33:3, 463-477
125
J. Main, H. Thomas. (2004) How should we manage the patient?. Journal of Viral Hepatitis 11:s1, 19-22
126
Ira M. Jacobson, Furqaan Ahmed, Mark W Russo, Edward Lebovics, Douglas T. Dieterich, Stephen P. Esposito, Nancy Bach, Franklin Klion, Hillel Tobias, Louis Antignano, Robert S. Brown, David Gabbaizadeh, Jane Geders, Hulya Levendoglu. (2004) Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT. The American Journal of Gastroenterology 99:9, 1700-1705
127
Bruce R. Bacon. (2004) Chronic Hepatitis C and Normal ALT: Considerations for Treatment. The American Journal of Gastroenterology 99:9, 1706-1707
128
B. Wang, M.J. Higgins, S. Kleinman, G.B. Schreiber, E.L. Murphy, S.A. Glynn, D.J. Wright, C.C. Nass, D. Chang, M.P. Busch, for the Retrovirus Epidemiology Donor Study. (2004) Comparison of demographic and donation profiles and transfusion-transmissible disease markers and risk rates in previously transfused and nontransfused blood donors. Transfusion 44:8, 1243-1251
129
Bruno Galperim, Hugo Cheinquer, Airton Stein, André Fonseca, Vagner Lunge, Nilo Ikuta. (2004) Intranasal cocaine use does not appear to be an independent risk factor for HCV infection. Addiction 99:8, 973-977
130
K. Rajender Reddy. (2004) CON: Most Patients Should Not be Treated. The American Journal of Gastroenterology 99:6, 973-975
131
Jonathan M. Koff, Zobair Younossi. (2004) PRO: Most Patients Should be Treated. The American Journal of Gastroenterology 99:6, 972-973
132
Brian L. Pearlman. (2004) Hepatitis C Infection: A Clinical Review. Southern Medical Journal 97:4, 365-373
133
Doris B. Strader, Teresa Wright, David L. Thomas, Leonard B. Seeff. (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:4, 1147-1171
134
S.L. Orton, S.L. Stramer, R.Y. Dodd, M.J. Alter. (2004) Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion 44:2, 275-281
135
MICHINORI KOHARA, KAZUAKI INOUE. (2004) 'Virus and Interferon' Mechanism of persistence in HCV infection.. Uirusu 54:2, 197-204
136
James M. McMahon, Stephanie Tortu. (2003) A Potential Hidden Source of Hepatitis C Infection Among Noninjecting Drug Users. Journal of Psychoactive Drugs 35:4, 455-460
137
Lawrence T. Goodnough. (2003) Risks of blood transfusion. Critical Care Medicine 31:Supplement, S678-S686
138
Gwendolyn P. Hammer, Timothy A. Kellogg, Willi C. McFarland, Ernest Wong, Brian Louie, Ian Williams, James Dilley, Kimberly Page-Shafer, Jeffrey D. Klausner. (2003) Low Incidence and Prevalence of Hepatitis C Virus Infection Among Sexually Active Non-Intravenous Drug-Using Adults, San Francisco, 1997–2000. Sexually Transmitted Diseases 30:12, 919-924
139
Vinod R. Hegde, Haiyan Pu, Mahesh Patel, Pradip R. Das, Nancy Butkiewicz, Gladys Arreaza, Vincent P. Gullo, Tze-Ming Chan. (2003) Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease. Bioorganic & Medicinal Chemistry Letters 13:17, 2925-2928
140
Lawrence Goodnough, John DiPersio. Transfusion considerations. In: Management of Infection in Oncology Patients. CRC Press, 2003:431-441.
141
Beryl A. Koblin, Stephanie H. Factor, Yingfeng Wu, David Vlahov. (2003) Hepatitis C virus infection among noninjecting drug users in New York City. Journal of Medical Virology 70:3, 387-390
142
Gianluca Quaglio, Fabio Lugoboni, Benedetta Pajusco, Maddalena Sarti, Giorgio Talamini, Alessandro Lechi, Paolo Mezzelani, Don C. Des Jarlais. (2003) Factors Associated with Hepatitis C Virus Infection in Injection and Noninjection Drug Users in Italy. Clinical Infectious Diseases 37:1, 33-40
143
Chun-Jen Liu, Pei-Jer Chen, Wen-Yi Shau, Jia-Horng Kao, Ming-Yang Lai, Ding-Shinn Chen. (2003) Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. Liver International 23:3, 148-155
144
C. Puoti, M. Guido, A. Mangia, M. Persico, D. Prati. (2003) Clinical management of HCV carriers with normal aminotransferase levels. Digestive and Liver Disease 35:5, 362-369
145
Douglas B. Nelson. (2003) Infectious disease complications of GI endoscopy: Part II, exogenous infections. Gastrointestinal Endoscopy 57:6, 695-711
146
ROBERT A. GUNN, PAULA J. MURRAY, CAROLYN H. BRENNAN, DAVID B. CALLAHAN, MIRIAM J. ALTER, HAROLD S. MARGOLIS. (2003) Evaluation of Screening Criteria to Identify Persons With Hepatitis C Virus Infection Among Sexually Transmitted Disease Clinic Clients. Sexually Transmitted Diseases 30:4, 340-344
147
F. T. Peters, H. H. Maurer, P. Hellstern. (2003) Prevalence of illicit drug use in plasmapheresis donors. Vox Sanguinis 84:2, 91-95
148
Naoshi Horikawa, Tomoko Yamazaki, Namiki Izumi, Masakatsu Uchihara. (2003) Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. General Hospital Psychiatry 25:1, 34-38
149
Tommy Yen, Emmet B. Keeffe, Aijaz Ahmed. (2003) The Epidemiology of Hepatitis C Virus Infection. Journal of Clinical Gastroenterology 36:1, 47-53
150
Youyin Choy, Lisa Gittens-Williams, Joseph Apuzzio, Joan Skurnick, Carl Zollicoffer, Peter G. McGovern. (2003) Risk Factors for Hepatitis C Infection Among Sexually Transmitted Disease-Infected, Inner City Obstetric Patients. Infectious Diseases in Obstetrics & Gynecology 11:4, 191-198
151
Susan Simon, Gabor Lotz, Fritz Kury, Birgit Reipert, Alexander Steinkasserer, Martha M. Eibl, Zsuzsa Schaff. In situ localization of PCR-amplified hepatitis C virus RNA on human erythrocytes. In: Frontiers in Viral Hepatitis. Elsevier, 2003:131-138.
152
Miriam J. Alter. (2002) Prevention of spread of hepatitis C. Hepatology 36:S1, S93-S98
153
Mark S. Sulkowski. (2002) Hepatitis C virus infection in HIV-infected patients. Current Hepatitis Reports 1:1, 16-22
154
Jay H. Hoofnagle. (2002) Course and outcome of hepatitis C. Hepatology 36:S1, S21-S29
155
Bruce R. Bacon. (2002) Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36:S1, S179-S184
156
Lutz G Guertler. (2002) Virus safety of human blood, plasma, and derived products. Thrombosis Research 107, S39-S45
157
Seyed Moayed Alavian, Bardia Gholami, Sadegh Masarrat. (2002) Hepatitis C risk factors in Iranian volunteer blood donors: A case-control study. Journal of Gastroenterology and Hepatology 17:10, 1092-1097
158
Caroline A. Sabin, Vince Emery, Helen L. Devereux, Anja Griffioen, Jeremy Bishop, Geoff Dusheiko, Thynn Thynn Yee, Esteban Herrero-Martinez, Christine A. Lee. (2002) Long-term patterns of hepatitis C virus RNA concentrations in a cohort of HIV seronegative men with bleeding disorders. Journal of Medical Virology 68:1, 68-75
159
Norbert Brau, Edmund J. Bini, Azra Shahidi, Ayse Aytaman, Peiying Xiao, Saray Stancic, Robert Eng, Sheldon T. Brown, Fiorenzo Paronetto. (2002) Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York city metropolitan area1. The American Journal of Gastroenterology 97:8, 2071-2078
160
Sumathi Sivapalasingam, Sharp F. Malak, John F. Sullivan, Jonathan Lorch, Kent A. Sepkowitz. (2002) High Prevalence of Hepatitis C Infection Among Patients Receiving Hemodialysis at an Urban Dialysis Center • . Infection Control and Hospital Epidemiology 23:6, 319-324
161
Peter M. Rosenberg. (2002) Hepatitis C: A Clinician???s View at the Turn of the Millennium. Infectious Diseases in Clinical Practice 11:4, 205-210
162
Kathleen Iosue. (2002) Chronic Hepatitis C: Latest Treatment Options. The Nurse Practitioner 27:4, 32-33
163
K. A. Page-Shafer, B. Cahoon-Young, J. D. Klausner, S. Morrow, F. Molitor, J. Ruiz, W. McFarland. (2002) Hepatitis C Virus Infection in Young, Low-Income Women: The Role of Sexually Transmitted Infection as a Potential Cofactor for HCV Infection. American Journal of Public Health 92:4, 670-676
164
M. I. Memon, M. A. Memon. (2002) Hepatitis C: an epidemiological review. Journal of Viral Hepatitis 9:2, 84-100
165
A DIMARTINI, R WEINRIEB, M FIREMAN. (2002) Liver transplantation in patients with alcohol and other substance use disorders. Psychiatric Clinics of North America 25:1, 195-209
166
Jean Ndjomou, Bernd Kupfer, Bettina Kochan, Leopold Zekeng, Lazare Kaptue, Bertfried Matz. (2002) Hepatitis C virus infection and genotypes among human immunodeficiency virus high-risk groups in Cameroon. Journal of Medical Virology 66:2, 179-186
167
Sue C. Eng, Kris V. Kowdley. (2002) DOES EARLY TREATMENT OF ACUTE HEPATITIS C VIRUS INFECTION WITH INTERFERON ALFA-2B PREVENT THE DEVELOPMENT OF CHRONIC HEPATITIS?. Evidence-Based Gastroenterology 3:1, 9-11
168
Robert E. Lanford, Catherine Bigger. (2002) Advances in Model Systems for Hepatitis C Virus Research. Virology 293:1, 1-9
169
Scott D. Rhodes, Ralph J. DiClemente, Heather Cecil, Kenneth C. Hergenrather, Leland J. Yee. (2002) Risk Among Men Who Have Sex With Men in the United States: A Comparison of an Internet Sample and a Conventional Outreach Sample. AIDS Education and Prevention 14:1, 41-50
170
Andrew Rosenblum, Larry Nuttbrock, Hunter L. McQuistion, Stephen Magura, Herman Joseph. (2001) Hepatitis C and Substance Use in a Sample of Homeless People in New York City. Journal of Addictive Diseases 20:4, 17-27
171
Paul D. Mintz, MD. (2001) NISHOT. American Journal of Clinical Pathology 116:6, 802-805
172
John M. O???Brien, Katarzyna E. Kruzel, Michael G. Wandell, Ilia V. Vinogradov, John N. Sheagren, Allan P. Frank. (2001) Detection of Hepatitis C Antibody With At-Home Collection Kits Using an Innovative Laboratory Algorithm. Infectious Diseases in Clinical Practice 10:9, 474-480
173
PIETRO FILIPPINI, NICOLA COPPOLA, CARLO SCOLASTICO, GIOVANNI ROSSI, MIRELLA ONOFRIO, EVANGELISTA SAGNELLI, FELICE PICCININO. (2001) Does HIV Infection Favor the Sexual Transmission of Hepatitis C?. Sexually Transmitted Diseases 28:12, 725-729
174
Livia Biancone, Maria Pavia, Giovanna Del Vecchio Blanco, Renata D'Incà, Fabiana Castiglione, Francesca De Nigris, Patrizia Doldo, Cristina Cosco, Piero Vavassori, Giampaolo P. Bresci, Arrigo Arrigoni, Giuseppina Cadau, Ivan Monteleone, Antonio Rispo, Walter Fries, Bruna Mallardi, Giancarlo C. Sturniolo, Francesco Pallone. (2001) Hepatitis B and C Virus Infection in Crohn's Disease. Inflammatory Bowel Diseases 7:4, 287-294
175
Mark S. Sulkowski. (2001) Hepatitis C virus infection in HIV-infected patients. Current Infectious Disease Reports 3:5, 469-476
176
Vincent G. Bain. (2001) Effect of HCV viral dynamics on treatment design: lessons learned from HIV. The American Journal of Gastroenterology 96:10, 2818-2828
177
SCOTT D. RHODES, RALPH J. DICLEMENTE, LELAND J. YEE, KENNETH C. HERGENRATHER. (2001) Factors Associated With Testing for Hepatitis C in an Internet-Recruited Sample of Men Who Have Sex With Men. Sexually Transmitted Diseases 28:9, 515-520
178
T. M. Shehab, S. S. Sonnad, A. S. F. Lok. (2001) Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. Journal of Viral Hepatitis 8:5, 377-383
179
Lauer , Georg M. , Walker , Bruce D. , . (2001) Hepatitis C Virus Infection. New England Journal of Medicine 345:1, 41-52
Full Text180
A. E. T. Yeo, M. Ghany, C. Conry-Cantilena, J. C. Melpolder, D. E. Kleiner, J. W. K. Shih, J. H. Hoofnagle, H. J. Alter. (2001) Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. Journal of Viral Hepatitis 8:4, 256-263
181
Claudia C.Trasancos, Marion A. Kainer, Paul V. Desmond, Heath Kelly. (2001) Investigation of potential iatrogenic transmission of hepatitis C in Victoria, Australia. Australian and New Zealand Journal of Public Health 25:3, 241-244
182
Giuliano Ramadori, Volker Meier. (2001) Hepatitis C virus infection: 10 years after the discovery of the virus. European Journal of Gastroenterology & Hepatology 13:5, 465-471
183
Alfonso Paredes, Joan E. Zweben. (2001) The Hepatitis C Epidemic, Shall We Remain Silent?. Journal of Addictive Diseases 20:1, 1-7
184
ROBERT W. HALEY, R. PAUL FISCHER. (2001) Commercial Tattooing as a Potentially Important Source of Hepatitis C Infection. Medicine 80:2, 134-151
185
Alfred Prince. Hepatitis Viruses and Blood Transfusion. In: Blood Safety and Surveillance. CRC Press, 2001:279-293.
186
Sérgio de A. Nishioka, Theresa W. Gyorkos. (2001) Tattoos as risk factors for transfusion-transmitted diseases. International Journal of Infectious Diseases 5:1, 27-34
187
Travis W. Waldrep, Kimberly K. Summers, Philippe A. Chiliade. (2000) Coinfection with HIV and HCV: More Questions than Answers?. Pharmacotherapy 20:12, 1499-1507
188
M.H. Elghouzzi, F. Bouchardeau, J. Pillonel, E. Boiret, C. Tirtaine, V. Barlet, P. Moncharmont, P. Maisonneuve, M.C. Puy-Montbrun, D. Lyon-Caen, A.M. Courouce. (2000) Hepatitis C Virus: Routes of Infection and Genotypes in a Cohort of Anti-HCV-Positive French Blood Donors. Vox Sanguinis 79:3, 138-144
189
Tobias J. Legler, Joachim Riggert, Georg Simson, Cornelia Wolf, Andreas Humpe, Ullrich Munzel, Angela Uy, Michael Kohler, Klaus-Hinrich Heermann. (2000) Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection. Transfusion 40:10, 1192-1197
190
David H. Culver, Miriam J. Alter, Robert J. Mullan, Harold S. Margolis. (2000) Evaluation of the effectiveness of targeted lookback for HCV infection in the United States-interim results. Transfusion 40:10, 1176-1181
191
C. Puoti, R. Castellacci, F. Montagnese. (2000) Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?. Digestive and Liver Disease 32:7, 634-643
192
Prati, Zanella, Zanuso, Vianello, E. Della Torre, Mozzi, Carriero, Zahm, Donato, Colombo, Sirchia, . (2000) Sustained response to interferon-alpha2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. Journal of Viral Hepatitis 7:5, 352-360
193
Catherine Petruff Cheney, Sanjiv Chopra, Camilla Graham. (2000) HEPATITIS C. Infectious Disease Clinics of North America 14:3, 633-667
194
F. Bouchardeau, S. Laperche, J. Pillonel, M.H. Elghouzzi, P. Maisonneuve, C. Tirtaine, E. Boiret, A. Razer, A. Girault, M.J. Beaulieu, A.M. Courouce. (2000) GB Virus type C/HGV markers in HCV RNA-positive French blood donors: correlation with HCV genotypes and risk factors. Transfusion 40:7, 875-878
195
J.M. Lemaire, A.M. Courouce, C. Defer, F. Bouchardeau, J. Coste, O. Agulles, J.F. Cantaloube, V. Barlet, F. Barin, . (2000) HCV RNA in blood donors with isolated reactivities by third-generation RIBA. Transfusion 40:7, 867-870
196
M.A. Mahl, M. Hirsch, U. Sugg. (2000) Verification of the drug history given by potential blood donors: results of drug screening that combines hair and urine analysis. Transfusion 40:6, 637-641
197
Ann L. Silverman, Jatinder S. Sekhon, Steven J. Saginaw, Daniel Wiedbrauk, Mamtha Balasubramaniam, Stuart C. Gordon. (2000) Tattoo application is not associated with an increased risk for chronic viral hepatitis. The American Journal of Gastroenterology 95:5, 1312-1315
198
Mark S. Sulkowski, Eric E. Mast, Leonard B. Seeff, David L. Thomas. (2000) Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases 30:s1, S77-S84
199
P Pradat, C Trépo. (2000) HCV: epidemiology, modes of transmission and prevention of spread. Best Practice & Research Clinical Gastroenterology 14:2, 201-210
200
Roger Y. Dodd, Susan L. Stramer. (2000) Indeterminate results in blood donor testing: What you don't know can hurt you. Transfusion Medicine Reviews 14:2, 151-160
201
Edward L. Murphy, Stephen M. Bryzman, Simone A. Glynn, Dannie I. Ameti, Ruth A. Thomson, Alan E. Williams, Catharie C. Nass, Helen E. Ownby, George B. Schreiber, Fanhui Kong, Keith R. Neal, George J. Nemo. (2000) Risk factors for hepatitis C virus infection in United States blood donors. Hepatology 31:3, 756-762
202
David L. Thomas. (2000) Hepatitis C epidemiology: Injecting new tools in the field. Hepatology 31:3, 790-791
203
Ackerman, Ackerman, Paltiel. (2000) Intrafamilial transmission of hepatitis C virus: a systematic review. Journal of Viral Hepatitis 7:2, 93-103
204
Hugo R. Rosen. (2000) Primer on Hepatitis C for Hospital Epidemiologists • . Infection Control and Hospital Epidemiology 21:3, 229-234
205
J. -P. Allain. (2000) Genomic screening for blood-borne viruses in transfusion settings. Clinical and Laboratory Haematology 22:1, 1-10
206
Anthony L. Cunningham, Adrian Mindel, Dominic E. Dwyer. Global Epidemiology of Sexually Transmitted Diseases. In: Sexually Transmitted Diseases. Elsevier, 2000:3-42.
207
Daniel Lavanchy, Brian McMahon. 10 Worldwide prevalence and prevention of hepatitis c. Elsevier, 2000:185-IV.
208
Miriam J. Alter, Yvan J.F. Hutin, Gregory L. Armstrong. 9 Epidemiology of hepatitis C. Elsevier, 2000:169-183.
209
M JONAS. (2000) 20 Hepatitis C in children. Biomedical Research Reports 2, 389-403
210
(1999) Prevalence of Hepatitis C Virus Infection in the United States. New England Journal of Medicine 341:27, 2093-2095
Free Full Text211
ROWLAND WATSON, NICK CROFTS, CREINA MITCHELL, CAMPBELL AITKEN, JANE HOCKING, SANDRA THOMPSON. (1999) Risk factors for hepatitis C transmission in the Victorian population: a telephone survey. Australian and New Zealand Journal of Public Health 23:6, 622-626
212
M. Rotily, C. Vernay-Vaisse, S. Rousseau, M. Bourliere, P. Gallian, A. Galinier-Pujol. (1999) Prevalence of HCV and HIV antibodies and related risk factors among entrants to the main southeastern French prison. Clinical Microbiology and Infection 5:12, 733-739
213
Ian Williams. (1999) Epidemiology of hepatitis C in the United States. The American Journal of Medicine 107:6, 2-9
214
Tricia J. Brown, Angela Yen-Moore, Stephen K. Tyring. (1999) An overview of sexually transmitted diseases. Part II. Journal of the American Academy of Dermatology 41:5, 661-680
215
Hugo R. Rosen, Sunwen Chou, Anna W. Sasaki, David R. Gretch. (1999) Molecular epidemiology of hepatitis C infection in U.S. veteran liver transplant recipients: evidence for decreasing relative prevalence of genotype 1B. The American Journal of Gastroenterology 94:10, 3015-3019
216
Christian Trépo, Fabien Zoulim, Pierre Pradat. (1999) Viral hepatitis. Current Opinion in Infectious Diseases 12:5, 481-490
217
Vogt , Manfred , Lang , Thomas , Frösner , Gert , Klingler , Christiane Sendl , Anna F. , Zeller , Anita Wiebecke , Baldur , Langer , Barbara , Meisner , Hans , Hess , John , . (1999) Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor Screening. New England Journal of Medicine 341:12, 866-870
Free Full Text218
Hugo R Rosen, David R Gretch. (1999) Hepatitis C virus: current understanding and prospects for future therapies. Molecular Medicine Today 5:9, 393-399
219
Thomas M. Shehab, Seema S. Sonnad, Mark Jeffries, Naresh Gunaratnum, Anna S. Lok. (1999) Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology 30:3, 794-800
220
Alter , Miriam J. , Kruszon-Moran , Deanna , Nainan , Omana V. , McQuillan , Geraldine M. , Gao , Fengxiang , Moyer , Linda A. , Kaslow , Richard A. , Margolis , Harold S. , . (1999) The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994. New England Journal of Medicine 341:8, 556-562
Free Full Text221
Bruno Chanzy, Dominique Luu Duc-Bin, Béatrice Rousset, Patrice Morand, Christine Morel-Baccard, Bernard Marchetti, Jérome Fauconnier, Marie-Reine Mallaret, Jean Calop, Jean-Pierre Zarski, Jean-Marie Seigneurin. (1999) Effectiveness of a manual disinfection procedure in eliminating hepatitis C virus from experimentally contaminated endoscopes. Gastrointestinal Endoscopy 50:2, 147-151
222
KM Roy, J. Bagg. (1999) Hepatitis C virus and oral disease: a critical review. Oral Diseases 5:4, 270-277
223
Catherine Sartor, Remi Nicolas Charrel, Xavier de Lamballerie, Roland Sambuc, Philippe De Micco, Leon Boubli. (1999) Evaluation of a Disinfection Procedure for Hysteroscopes Contaminated by Hepatitis C Virus • . Infection Control and Hospital Epidemiology 20:6, 434-436
224
Tobias J. Legler, Michael Köhler, Klaus-Hinrich Heermann. (1999) High-throughput extraction, amplification, and detection (HEAD) of HCV-RNA in individual blood donations. Journal of Clinical Virology 13:1-2, 95-103
225
Ranga Balasekaran, Marc Bulterys, M. Mazen Jamal, Patrick G. Quinn, David E. Johnston, Betty Skipper, Sanjana Chaturvedi, Sanjeev Arora. (1999) A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States. The American Journal of Gastroenterology 94:5, 1341-1346
226
Hari S. Conjeevaram. (1999) Etiology of Hepatitis C: A Reassessment. The American Journal of Gastroenterology 94:5, 1135-1136
227
Kenny-Walsh , Elizabeth , . (1999) Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin. New England Journal of Medicine 340:16, 1228-1233
Free Full Text228
Gilles Delage, Claire Infante–Rivard, Jo–Anne Chiavetta, Bernard Willems, David Pi, Margaret Fast. (1999) Risk factors for acquisition of hepatitis C virus infection in blood donors: Results of a case-control study. Gastroenterology 116:4, 893-899
229
NANCY L. ERIKSEN. (1999) Perinatal Consequences of Hepatitis C. Clinical Obstetrics and Gynecology 42:1, 121-133
230
Patrick G. Quinn, M. Mazen Jamal, John D. Carey, Sanjeev Arora, Tanya Harris, David E. Johnston, Amnon Sonnenberg. (1999) A case-control study of the factors associated with spontaneous resolution of hepatitis C viremia. The American Journal of Gastroenterology 94:3, 668-673
231
Goodnough , Lawrence T. , Brecher , Mark E. , Kanter , Michael H. , AuBuchon , James P. , . (1999) Transfusion Medicine — Blood Transfusion. New England Journal of Medicine 340:6, 438-447
Full Text232
Peer B. Christensen, Karin Groenbaek, Henrik B. Krarup, Johannes Gaub, Axel Møller, Peter Skinhøj, Helmer Ring-Larsen, Karin Groenbaek, Henrik B. Krarup, Dickmeiss Dickmeiss, Per S. Wantzin. (1999) Transfusion-acquired hepatitis C: the Danish lookback experience. Transfusion 39:2, 188-193
233
Anne Spaulding, Carolyn Greene, Kerith Davidson, Michelle Schneidermann, Josiah Rich. (1999) Hepatitis C in State Correctional Facilities. Preventive Medicine 28:1, 92-100
234
Anne C. E. Moor, Tom M. A. R. Dubbelman, John VanSteveninck, Anneke Brand. (1999) Transfusion-transmitted diseases: risks, prevention and perspectives. European Journal of Haematology 62:1, 1-18
235
Virge James, Patricia E. Hewitt, John A.J. Barbara. (1999) How understanding donor behavior should shape donor selection. Transfusion Medicine Reviews 13:1, 49-64
236
Miriam J. Alter. (1999) Hepatitis C virus infection in the United States. Journal of Hepatology 31, 88-91
237
C. Trépo, P. Pradat. (1999) Hepatitis C virus infection in Western Europe. Journal of Hepatology 31, 80-83
238
Jean-Pierre Zarski, Vincent Leroy. (1999) Counselling patients with hepatitis C. Journal of Hepatology 31, 136-140
239
Daniel Lavanchy. (1999) Hepatitis C: public health strategies. Journal of Hepatology 31, 146-151
240
Patrick Marcellin. (1999) Hepatitis C: the clinical spectrum of the disease. Journal of Hepatology 31, 9-16
241
Rune Wejstål. (1999) Sexual transmission of hepatitis C virus. Journal of Hepatology 31, 92-95
242
RONALD C. HERSHOW, LESLIE A. KALISH, BEVERLY SHA, MICHELE TILL, MARDGE COHEN. (1998) Hepatitis C Virus Infection in Chicago Women With or at Risk for HIV Infection. Sexually Transmitted Diseases 25:10, 527-532
243
J.Mark Jackson, Jeffrey P. Callen. (1998) Scarring alopecia and sclerodermatous changes of the scalp in a patient with hepatitis C infection. Journal of the American Academy of Dermatology 39:5, 824-826
244
Thomas R. Riley, Jill P. Smith. (1998) Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis c: a case series. The American Journal of Gastroenterology 93:9, 1563-1565
245
Flavia Bortolotti, Massimo Resti, Raffaella Giacchino, Carlo Crivellaro, Lucia Zancan, Chiara Azzari, Nadia Gussetti, Loredana Tasso, Stefania Faggion. (1998) Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. The Journal of Pediatrics 133:3, 378-381
246
MARCELLO PIAZZA, LUCIANO SAGLIOCCA, GRAZIA TOSONE, VINCENZO GUADAGNINO, MARIA ANTONIA STAZI, RAFFAELE ORLANDO, GUGLIELMO BORGIA, DOMENICO ROSA, SERGIO ABRIGNANI, FILIPPO PALUMBO, ALDO MANZIN, MASSIMO CLEMENTI. (1998) Sexual Transmission of Hepatitis C Virus and Prevention with Intramuscular Immunoglobulin. AIDS Patient Care and STDs 12:8, 611-618
247
H.H. Lee, J-P. Allain. (1998) Genomic Screening for Blood-Borne Viruses in Transfusion Settings. Vox Sanguinis 74:S2, 119-123
248
P.V. Holland. (1998) Post-Transfusion Hepatitis: Current Risks and Causes. Vox Sanguinis 74:S2, 135-141
249
K. Sazama. (1998) Interactions between Science, Government and Media on Selection and Testing of Donors. Vox Sanguinis 74:S2, 503-506
250
J.E. Menitove. (1998) Hemovigilance in the United States of America. Vox Sanguinis 74:S2, 447-455
251
(1998) Calendar. Transfusion 38:5, 514-514
252
Steven L. Flamm, Robert A. Parker, Sanjiv Chopra. (1998) Risk Factors Associated With Chronic Hepatitis C Virus Infection: Limited Frequency of an Unidentified Source of Transmission. The American Journal of Gastroenterology 93:4, 597-600
253
A LLAIN. (1998) Screening blood for viral genomes: which way to go?. Transfusion Medicine 8:1, 5-7
254
Miriam J. Alter, Eric E. Mast, Linda A. Moyer, Harold S. Margolis. (1998) HEPATITIS C. Infectious Disease Clinics of North America 12:1, 13-26
255
CAROLINE A. SABIN. (1998) Hepatitis C Virus and HIV Coinfection. AIDS Patient Care and STDs 12:3, 199-207
256
Adrian M Di Bisceglie. (1998) Hepatitis C. The Lancet 351:9099, 351-355
257
NURUL AKBAR, BASTAMAN BASUKI, DAVID H GARABRANT, ALI SULAIMAN, HM SJAIFOELLAH NOER. (1997) Ethnicity, socioeconomic status, transfusions and risk of hepatitis B and hepatitis C infection. Journal of Gastroenterology and Hepatology 12:11, 752-757
258
MATTHEW E. CRAMP, ROGER WILLIAMS. (1997) Hepatitis in alcohol and drug misusers: practical issues. Addiction Biology 2:4, 411-420
259
Clay M. Shearer, J.Mark Jackson, Jeffrey P. Callen. (1997) Symmetric polyarthritis with livedo reticularis: A newly recognized manifestation of hepatitis C virus infection. Journal of the American Academy of Dermatology 37:4, 659-661
260
R. Wyld, J.R. Robertson, R.P. Brettle, J. Mellor, L. Prescott, P. Simmonds. (1997) Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. Journal of Infection 35:2, 163-166
261
Mei-Shang Ho, Chien-Pang Hsu, Yau Yuh, Chwan-Chuen King, Jung-Fa Tsai, Yi-Chien Mau, Li-Ching Hsu, Wan-Hwa Chao. (1997) High rate of hepatitis C virus infection in an isolated community: Persistent hyperendemicity or period-related phenomena?. Journal of Medical Virology 52:4, 370-376
262
Antoni Ribas, Anna Butturini, Anna Locasciulli, Maurizio Aricó, Robert Peter Gale. (1997) How important is hepatitis C virus (HCV)-infection in persons with acute leukemia?. Leukemia Research 21:8, 785-788
263
Bronowicki , Jean-Pierre , Venard , Véronique , Botté , Christine , Monhoven , Nathalie , Gastin , Isabelle , Choné , Laurence , Hudziak , Hervé , Rhin , Bertrand , Delanoë , Christophe , LeFaou , Alain , Bigard , Marc-André , Gaucher , Pierre , . (1997) Patient-to-Patient Transmission of Hepatitis C Virus during Colonoscopy. New England Journal of Medicine 337:4, 237-240
Free Full Text264
Hugo R. Rosen. (1997) Acquisition of hepatitis C by a conjunctival splash. American Journal of Infection Control 25:3, 242-247
265
Charles D. Kaplan, Dorette A. Courtar. (1997) Drugs and sexual health. Current Opinion in Psychiatry 10:3, 199-204
266
Greg A. Knoll, Martha R. Tankersley, Jeannette Y. Lee, Bruce A. Julian, John J. Curtis. (1997) The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. American Journal of Kidney Diseases 29:4, 608-614
267
Cyrus R. Kapadia. (1997) Oxides, Onions, and Other Matters Gastrointestinal-1996-A Perspective. Journal of Clinical Gastroenterology 24:3, 133-139
268
Hoofnagle , Jay H. Di Bisceglie , Adrian M. . (1997) The Treatment of Chronic Viral Hepatitis. New England Journal of Medicine 336:5, 347-356
Full Text269
Holland , Paul V. , . (1996) Viral Infections and the Blood Supply. New England Journal of Medicine 334:26, 1734-1735
Full Text
